The Role of AI-Ready Data in Multi-Modal Analysis and Decision-Making

In biopharma and healthcare research, the abundance of artificial intelligence (AI) algorithms and growing computing power has brought disruption to the industry. This led to an increase in multi-modal data and the analysis of this data can reveal insights that were previously unimaginable. Integrating these diverse data types into a cohesive, actionable format is a major bottleneck in biopharma and clinical research. Every type of data comes with its set of challenges, for example, clinical data is mostly unstructured, omics data tends to be massive and complex, and imaging data requires specialized processing. To add to this complexity, we face issues like inconsistent formats, missing metadata, and the need to ensure data interoperability. These challenges slow down the journey from data to insights, making it difficult to leverage the full potential of multi-modal analysis.
Source Url

elucidata .io
Author: elucidata .io

Website: https://www.elucidata.io/ Website: https://www.elucidata.io/ Elucidata leverages its platform, Polly to augment the quality of data in pre-clinical drug discovery. It curates multi-omics and assay data to make them ML-ready or analysis-ready. Our exceptional multi-disciplinary team of experts use Polly’s powerful curation engine to harmonize a diverse array of data-types, curate metadata and process data consistently at affordable costs while maintaining information-richness. We are one of the only companies to offer a tech-enabled approach to multi-modal data curation that serves the life science industry. Polly’s technology and experts have helped R&D teams arrive at multiple validated drug targets across immunology, oncology, and metabolomic disorders. Currently, 25+ research organizations, including 4 of the largest 10 pharma companies are using Polly and its allied solutions to accelerate their discovery programs. Many other data-driven healthcare companies also use Polly to process, harmonize and store public or in-house biomedical data. Address: 114 Sansome Street, Suite 250 San Francisco, CA 94104 Phone No: 9716140329 Contact Email: info@elucidata.io

elucidata .io

Website: https://www.elucidata.io/ Website: https://www.elucidata.io/ Elucidata leverages its platform, Polly to augment the quality of data in pre-clinical drug discovery. It curates multi-omics and assay data to make them ML-ready or analysis-ready. Our exceptional multi-disciplinary team of experts use Polly’s powerful curation engine to harmonize a diverse array of data-types, curate metadata and process data consistently at affordable costs while maintaining information-richness. We are one of the only companies to offer a tech-enabled approach to multi-modal data curation that serves the life science industry. Polly’s technology and experts have helped R&D teams arrive at multiple validated drug targets across immunology, oncology, and metabolomic disorders. Currently, 25+ research organizations, including 4 of the largest 10 pharma companies are using Polly and its allied solutions to accelerate their discovery programs. Many other data-driven healthcare companies also use Polly to process, harmonize and store public or in-house biomedical data. Address: 114 Sansome Street, Suite 250 San Francisco, CA 94104 Phone No: 9716140329 Contact Email: info@elucidata.io